ArticleFrontiers in immunology2026
Serum steroid hormone profiles in reproductive-age women with systemic lupus erythematosus: associations with clinical manifestations and disease activity.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the serum steroid hormone profile in reproductive-age women with systemic lupus erythematosus (SLE) and evaluate its associations with clinical manifestations and disease activity. Methods: This cross-sectional study enrolled 39 newly diagnosed, treatment-naïve female SLE patients and 37 matched healthy controls. Fasting blood samples were collected in the morning. Serum levels of a comprehensive panel of steroid hormones (including glucocorticoids, mineralocorticoids, androgens, estrogens, and progestogens) were simultaneously quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Clinical parameters and disease activity (SLEDAI-2000) were assessed. Results: SLE patients exhibited a globally altered steroid hormone profile compared to controls. Levels of key androgens (androstenedione, testosterone, dihydrotestosterone, dehydroepiandrosterone), glucocorticoids (cortisol, corticosterone, cortisone), and mineralocorticoids (aldosterone) were significantly lower in the SLE group. In contrast, serum melatonin was markedly elevated. Analysis across menstrual phases revealed consistently lower progesterone and 17-hydroxyprogesterone, but higher estradiol levels in SLE patients. Correlation analyses demonstrated that lower glucocorticoid and androgen levels were associated with increased inflammatory markers (e.g., lower complement C3/C4, higher IL-6) and hematological abnormalities. Crucially, reduced aldosterone levels correlated with higher 24-hour proteinuria and SLEDAI scores. Conclusion: Reproductive-age women with SLE display a distinct steroid hormone signature suggestive of hypothalamic-pituitary-adrenal (HPA) axis suppression, characterized by a broad deficiency in adrenal and gonadal steroids alongside hyperestrogenism and elevated melatonin. These hormonal imbalances are significantly correlated with disease activity, inflammation, and renal involvement. The serum steroid hormone profile may serve as a valuable biomarker for assessing SLE activity and provides insights into the endocrine-immune interplay in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.